fluticasone and Hyperplasia

Presenile diffuse familial sebaceous hyperplasia (PDFSH) presents as extensive yellowish papules with central umbilication on the face without involvement of periorificial regions and occurs in adolescents or young adults with a positive family history. Thirteen cases of PDFSH have been reported in the English-language published work, 10 of which responded to oral isotretinoin from 0.5 to 1 mg/kg per day but recurrences were often observed. Herein, we report two cases of PDFSH, which were successfully managed without recurrence with prolonged low-dose isotretinoin (0.2 mg/kg per day, a cumulative dose of 41 and 64 mg/kg, respectively). Treatment protocols among different published works were reviewed to verify the efficacy of isotretinoin.

Topics: Administration, Cutaneous; Administration, Oral; Adult; Anti-Bacterial Agents; Biopsy; Cheek; Clinical Protocols; Dermatologic Agents; Facial Dermatoses; Female; Fluticasone; Humans; Hyperplasia; Isotretinoin; Maintenance Chemotherapy; Male; Recurrence; Sebaceous Glands; Treatment Outcome; Tretinoin

Eosinophilic esophagitis is an increasingly recognized disorder with distinctive endoscopic, histologic, and allergic features. Although several therapies are advocated, no placebo-controlled trials have been conducted. We aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinophilic esophagitis.. We conducted a randomized, double-blind, placebo-controlled trial of swallowed FP in pediatric patients with active eosinophilic esophagitis. Thirty-six patients were randomly assigned to receive either 880 mug of FP (21 patients) or placebo (15 patients) divided twice daily for 3 months. The primary end point was histologic remission, defined by a peak eosinophil count of

Topics: Adolescent; Age Factors; Androstadienes; Body Height; Body Weight; CD8-Positive T-Lymphocytes; Child; Child, Preschool; Double-Blind Method; Eosinophilia; Esophagitis; Female; Fluticasone; Humans; Hyperplasia; Infant; Male